Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.

ABSTRACT: Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials & methods: Mixed-effect Models for Repeated Measures were applied to HRQoL data (FACT-M; EQ-5D-5L) to assess changes over time. Clinically derived progression-free survival was compared with HRQoL deterioration-free survival. Results: Overall, we saw relative stability in HRQoL among 116 included patients, with nonprogression associated with statistically and clinically meaningful better HRQoL compared with progressive disease. Deterioration-free survival rates (49-72% at 6 months, 40-58% at 12 months) were consistently higher/better compared with prog

SUBMITTER: Bharmal M 

PROVIDER: S-EPMC9437770 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature